Ok now that I have calmed down a bit...
But as always here
Ok now that I have calmed down a bit...
But as always here goes my positive and negative summation:
Positives:
-good leadership with great past success. Blueprint for success...
-lazer focusing on 4 can products
-new labels,cans,size and formula.
-hiring a VP of sales and one for a marketing position
-have 1 major player for financing
-did 2 focus groups.
-may be easier to get rebranded product on shelves due to MGMT contacts, past success and leadership
Challenges:
-water on hold
-friar tuck on hold
-international on hold
-no CBD drinks for now due to FDA
-Share structure
-no infomercials
-Have to rebrand and roll out product again
-need that financing- it is not a done deal
-old drinks were good , not sure of new drinks -TBD
-not sure of market reaction (hoping to be surprised)
-Lily li a non factor or not mentioned.
so that is all folks. I am praying that my initial reaction was a just a wrong reaction by myself. Going to hit the gym for a couple hours..
good luck.
3
Rocky Mountain High Brands, Inc. (RMHB) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Papa John’s $2.7 Billion Takeover Bid: Insights into Potential Value Recently, shares of Papa John’s International Inc (NASDAQ:PZZA) experienced a notable surge, leading to a halt in trading due to high volatility. This surprising movement came in light of credible reports suggesting a take-private cash offer of $65 per share from TriArtisan Capital Advisors, totaling...
Continue Reading
Octopus Apollo VCT plc AGM Results Overview Octopus Apollo VCT plc recently conducted its Annual General Meeting (AGM), showcasing significant engagement from shareholders. The meeting aimed to discuss key resolutions impacting the future direction of the company. Voting Outcomes of the AGM The company disclosed that all resolutions were successfully passed during the...
Continue Reading
Carisma Therapeutics Showcases Strong Financial Performance Carisma Therapeutics Inc. (NASDAQ: CARM), a clinical-stage biopharmaceutical company, recently released its financial performance for the third quarter of 2024. With a focus on developing innovative immunotherapies, Carisma provided insight into its ongoing projects. Key Developments and Milestones Carisma's...
Continue Reading
Overview of the Epinephrine Market The global epinephrine market is on a significant upswing, with recent evaluations estimating its value at USD 3.11 billion and a projected growth to approximately USD 6.39 billion within the next decade. As a critical hormone and neurotransmitter produced by the adrenal glands, epinephrine is essential in treating severe allergic...
Continue Reading
Canadian North Resources Makes Significant Progress in Operational Strategy Highlights: Canadian North has expanded its bio-metallurgical programs significantly, achieving impressive nickel and cobalt extraction rates through innovative bio-leaching tests. The focus remains on extracting copper and other precious group elements (PGE) metals from the Ferguson Lake Project....
Continue Reading